TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM571501

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
JCR PHARMACEUTICALS CO., LTD.		04/10/2020	Corporation: JAPAN

RECEIVING PARTY DATA

Name:	ARMAGEN, INC.
Street Address:	26679 Agoura Road
City:	Calabasas
State/Country:	CALIFORNIA
Postal Code:	91302
Entity Type:	Corporation: DELAWARE

PROPERTY NUMBERS Total: 1

Property Type	Number	Word Mark
Registration Number:	3522417	ARMAGEN

CORRESPONDENCE DATA

Fax Number: 4156932222

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 4156932000
Email: crhem@cooley.com
Correspondent Name: Cooley LLP
Address Line 1: 101 California Street, 5th Floor
Address Line 4: San Francisco, CALIFORNIA 94111

CH $40.00 3522417

ATTORNEY DOCKET NUMBER:	335866-101
NAME OF SUBMITTER:	C. Rhem
SIGNATURE:	/CR/
DATE SIGNED:	04/10/2020

Total Attachments: 6
source=JCR - ArmaGen - IP Release Executed#page1.tif
source=JCR - ArmaGen - IP Release Executed#page2.tif
source=JCR - ArmaGen - IP Release Executed#page3.tif
source=JCR - ArmaGen - IP Release Executed#page4.tif

source=JCR - ArmaGen - IP Release Executed#page5.tif
source=JCR - ArmaGen - IP Release Executed#page6.tif

RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY

This Release of Security Interest in Intellectual Property is made as of April 10, 2020, by JCR PHARMACEUTICALS CO., LTD., a company organized under the laws of Japan ("JCR") in favor of ARMAGEN, INC., a Delaware corporation ("Grantor").

Recital

WHEREAS, JCR acquired a security interest in the patents and trademarks described on Exhibits A and B attached hereto (collectively, the "Intellectual Property") under that certain Assignment of Intellectual Property Security Agreement, dated as of November 15, 2019 (the "IP Security Agreement"), by and between JCR and Oxford Finance LLC, a Delaware limited liability company, and recorded with the U.S. Patent and Trademark Office as set forth on Exhibits A and B.

WHEREAS, Grantor has no outstanding obligations to JCR under the terms of the IP Security Agreement, and JCR agrees to release its security interest in the Intellectual Property.

Agreement

Now, therefore, JCR agrees that it terminates and releases its security interest in the Intellectual Property, terminates the IP Security Agreement, and reassigns to Grantor, without warranty or recourse, all interest of JCR in the Intellectual Property.

[Signature Page Follows]

JCR PHARMACEUTICALS CO., LTD.

By: 本多 裕

Name: Yutaka Honda
Title: Executive Director,
Corporate Planning Division

3-19 Kasuga-cho
Ashiya, Japan 659-0021

EXHIBIT A

Patents

Description	Registration/ Application Number	Registration/ Application Date
FUSION PROTEINS FOR BLOOD-BRAIN BARRIER DELIVERY	2011205186 (Australia)	11/27/14
	2,625,293 (Canada)	10/18/16
	16171496.9 (EPO)	09/28/06
FUSION PROTEINS FOR DELIVERY OF ERYTHROPOIETIN TO THE CNS	11733492.0 (EPO)	01/14/11
FUSION PROTEINS FOR BLOOD-BRAIN BARRIER DELIVERY	5941607 (Japan)	05/27/16
	2014-116085 (Japan)	09/28/06
	2016-100640 (Japan)	09/28/06
FUSION PROTEINS FOR BLOOD-BRAIN BARRIER DELIVERY	US2006/038587 (PCT)	09/28/06
FUSION PROTEINS FOR DELIVERY OF ERYTHROPOIETIN TO THE CNS	US2011/21418 (PCT)	01/14/11
FUSION PROTEINS FOR BLOOD-BRAIN BARRIER DELIVERY	8,142,781 (US)	03/27/12
FUSION PROTEINS FOR DELIVERY OF ERYTHROPOIETIN TO THE CNS	8,124,095 (US)	02/28/12
NUCLEIC ACIDS ENCODING AND METHODS OF PRODUCING FUSION PROTEINS	8,053,569 (US)	11/08/11
AGENTS FOR BLOOD-BRAIN BARRIER DELIVERY	2007285763 (Australia)	03/29/12
	2,661,042 (Canada)	12/11/12
	2051734 (France)	10/05/16
	2051734 (Germany)	10/05/16
	5959795 (Japan)	07/01/16
	2014-043117 (Japan)	08/20/07
	US2007/76316 (PCT)	08/20/07
	2051734 (Switzerland)	10/05/16
	2051734 (United Kingdom)	10/05/16
GENETICALLY ENCODED MULTIFUNCTIONAL COMPOSITIONS BIDIRECTIONALLY TRANSPORTED BETWEEN PERIPHERAL BLOOD AND THE CNS	8,759,297 (US)	06/24/14
METHODS FOR DIAGNOSING AND TREATING CNS DISORDERS BY TRANS-BLOOD-BRAIN BARRIER DELIVERY OF PROTEIN COMPOSITIONS	8,497,246 (US)	07/30/13
FUSION ANTIBODIES THAT CROSS THE BLOOD-BRAIN BARRIER IN BOTH DIRECTIONS	7,741,446 (US)	06/22/10
MACROMOLECULAR COMPOSITIONS THAT CROSS THE BLOOD-BRAIN BARRIER AND METHODS OF USE THEREOF	14/192,792 (US)	02/27/14
	14/594,047 (US)	01/09/15

METHODS FOR DIAGNOSING CNS DISORDERS WITH FUSION ANTIBODIES THAT CROSS THE BLOOD-BRAIN BARRIER IN BOTH DIRECTIONS	8,753,610 (US)	06/17/14
METHODS AND COMPOSITIONS FOR INCREASING ALPHA-L-IDURONIDASE ACTIVITY IN THE CNS	2008282496 (Australia)	07/15/13
	2,694,762 (Canada)	07/25/08
	15175407.4 (EPO)	07/25/08
	5901877 (Japan)	03/18/16
	2014-156837 (Japan)	07/25/08
	2016-235211 (Japan)	07/25/08
	US2008/71121 (PCT)	07/25/08
	8,974,791 (US)	03/10/15
	9,367,400 (US)	02/14/17
	15/397,649 (US)	01/03/17
FUSION PROTEINS FOR DELIVERY OF GDNF TO THE CNS	14/144,460 (US)	12/30/13
	8,741,260 (US)	06/03/14
COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY OF IgG-DECOY RECEPTOR FUSION PROTEINS	2,748,889 (Canada)	03/18/10
	10754139.3 (EPO)	03/18/10
	5873003 (Japan)	01/22/16
	US2010/27882 (PCT)	03/18/10
	15/357,894 (US)	11/21/16
	9,533,055 (US)	01/03/17
METHODS AND COMPOSITIONS FOR INCREASING IDURONATE 2-SULFATASE ACTIVITY IN THE CNS	10822810.7 (EPO)	10/08/10
	2016-014716 (Japan)	10/08/10
	US2010/52113 (PCT)	10/08/10
	8,834,874 (US)	09/16/14
	14/305,402 (US)	06/16/14
METHODS AND COMPOSITIONS FOR INCREASING ARYLSULFATASE A ACTIVITY IN THE CNS	2012346448 (Australia)	01/03/18
	2,857,647 (Canada)	09/10/12
	12854380.8 (EPO)	09/10/12
	2014-544731 (Japan)	09/10/12
	2017-173010 (Japan)	09/10/12
	PCT/US2012/054520	09/10/12
	8,486,399 (US)	07/16/13
	8,715,661 (US)	05/06/14
	8,920,801 (US)	12/30/14
	14/538,721 (US)	11/11/14
METHODS AND COMPOSITIONS FOR INCREASING ENZYME	2014293626 (Australia)	05/19/14

ACTIVITY IN THE CNS	2,918,579 (Canada)	05/19/14
	14733798.1 (EPO)	05/19/14
	2016-529759 (Japan)	05/19/14
	PCT/US2014/038668	05/19/14
	14/281,803 (US)	05/19/14
METHODS AND COMPOSITIONS FOR INCREASING N-ACETYLGLUCOSAMINIDASE ACTIVITY IN THE CNS	14/994,067 (US)	01/12/16

JCR's security interest was recorded at the U.S. Patent and Trademark Office on November 18, 2019 at Reel Number 051042 and Frame Number 0528.

EXHIBIT B

Trademarks

Description	Registration/ Application Number	Registration/ Application Date
ARMAGEN	3522417	10/21/08

JCR's security interest was recorded at the U.S. Patent and Trademark Office on November 15, 2019 at Reel Number 006880 and Frame Number 0933.